Premium
Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
AIM 01 July 2009 ? NOTICE (470) 01/07/2009 7:00am CANCELLATION OF ADMISSION OF SECURITIES TO TRADING ON AIM ENTELOS INC. At the request of the company trading on AIM for the under-mentioned...
AIM 01 July 2009 ? NOTICE (470) 01/07/2009 7:00am CANCELLATION OF ADMISSION OF SECURITIES TO TRADING ON AIM ENTELOS INC. At the request of the company trading on AIM for the under-mentioned...
L Entelos, Inc. ("Entelos" or the "Company") today announces that the Company's shareholders overwhelmingly voted to approve a proposal to de-list its shares of common stock from the AIM Exchange...
L Entelos, Inc. ("Entelos" or the "Company") (LSE: ENTL), a leader in predictive disease simulation for pharmaceutical, health-care and consumer products applications, today announces the mailing...
L Entelos, Inc. ("Entelos" or the "Company") today announced that it intends to seek stockholder approval to cancel the trading of its shares of common stock on the AIM Exchange (the "Delisting...
L Entelos, Inc. Management Changes Entelos, Inc. ("Entelos" or the "Company") announces changes to its senior management team. Jim Neal is appointed as Acting President and Acting Chief Executive...
L On December 21, 2007, Entelos, Inc. ("Entelos" or the "Company") entered into a debt financing agreement with Imperium Master Fund, LTD ("Imperium") in which Imperium provided the Company...
L Entelos, Inc. Imperium Debt Financing On December 21, 2007, Entelos, Inc. ("Entelos" or the "Company") entered into a debt financing agreement with Imperium Master Fund, LTD ("Imperium") in...
L The Hamner Institutes for Health Sciences and Entelos, Inc. announced they have established a partnership to create a computer model of liver function in virtual patients ("virtual liver") that...
L Entelos, Inc. (LSE: ENTL), a leader in predictive disease simulation for pharmaceutical, health-care and consumer products applications, announced today that GlaxoSmithKline ("GSK") has signed...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
